Liz Morrell
MA MSc PhD FHEA
Senior Researcher
Liz joined Health Economics Research Centre (HERC) in February 2018, from the Centre for the Advancement of Sustainable Medical Innovation (CASMI) - a policy research group in Oxford’s Radcliffe Department of Medicine. Her work focused on the health economics of cancer drugs, exploring the impact of technology appraisal processes on patient access to drugs, and the value that society places on treating cancer relative to other conditions.
Since joining HERC, Liz has followed two strands of research: economic evaluation of genomic technologies including in low and middle income countries, and using choice experiments to understand patient and clinician behaviour related to antibiotic resistance
Before coming to Oxford, Liz worked as a freelance researcher with clients in pharmaceuticals and education, and as a product development manager in consumer healthcare.
Recent publications
Liquid biopsy for the diagnosis of EBV-positive Burkitt's lymphoma in endemic areas.
Journal article
Chamba C. et al, (2026), Nat Med
Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania.
Journal article
Jiang J. et al, (2026), BMC Med, 24
P38 "Tell Me a Story": A Randomized Study Comparing Tabulated and Narrative Presentations of a Discrete Choice Experiment
Conference paper
Morrell L. et al, (2025), Value in Health, 28, S34 - S34
Optimising antibiotic “review and revise” in acute/general medical inpatients: the Antibiotic Review Kit in Hospitals (ARK-Hospital) research programme including a stepped-wedge cluster-randomised trial
Journal article
Llewelyn MJ. et al, (2025), NIHR Journals Library
Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study.
Journal article
Morrell L. et al, (2025), Value Health Reg Issues, 48
